Jobs / United States / Astrazeneca Pharmaceuticals Lp
Study Physician, Immunology
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Cambridge Kendall SQ - MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles2 certified filings for “Study Physician Lung Cancer” (Medical Scientists, Except Epidemiologists) in DE: $218k–$309k, median $264k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
The Study Physician, Immunology is an expert clinical-development role within our Rheumatology therapeutic area. Working as the study-level clinical authority within a program led by the Global Clinical Program Lead (GCPL), you will provide expert medical and scientific input across our rheumatology programs. You will begin in Rheumatology and may contribute to additional indications, modalities, and clinical development programs as the portfolio evolves. You will partner closely with the Clinical Scientists on the study team and collaborate cross-functionally at the enterprise level, including with Oncology, Alexion, and development partners. The successful candidate will thrive in a fast-paced, proactive culture and be a strong communicator and collaborator, both internally and externally. You will report to the Global Clinical Head, Rheumatology, or their designee, and work in close partnership with the Global Clinical Program Lead, who leads the program's clinical development strategy. Typical Accountabilities • Provide expert medical and scientific input to cell-therapy and immunotherapy clinical-stage assets in development for Rheumatology and additional immune-mediated diseases. • Act as clinical authority representative for the study team. With senior support as needed, you will be responsible for the design, delivery, and interpretation of clinical studies from Phase 1 through pivotal, ensuring compliance with GCP. • Lead the medical assessment of causality, severity and benefit-risk for safety events, and provide medical sign-off on safety-related decisions such as dose holds and stopping-rule application. Own ongoing review and monitoring of clinical data for quality, data integrity, data-trend investigation, and safety, including SAEs, SUSARs, protocol deviations, and periodic review of emerging safety, efficacy, PK, and biomarker data both internally and via SRC/DMCs. • Represent the study at the Safety Review Committee, IDMC/DMC, and internal safety governance. Adjudicate complex clinical cases, including MS relapse adjudication, and sign off endpoint definitions and thresholds. • Support the clinical development strategy from early target identification through late phase, with senior support as necessary, and secure cross-functional alignment across the wider AZ organization. • Provide clinical and disease expertise to research, clinical pharmacology, translational medicine, regulatory, biostatistics, safety, the cell-therapy delivery team (including CMC), and commercial colleagues as part of a cross-functional team. • Follow medical developments in cell therapy and immune-mediated disease closely, and disseminate insight within Clinical Development and the wider organization to translate emerging data into innovative clinical plans. • Support the program at internal governance interactions and with external partners, as aligned with senior management. This includes investigators, key external experts, patient-advocacy groups, regulators, sites, and CROs. • Contribute medical content and final medical review to clinical sections of study- and program-level documents such as protocols, ICFs, IB, briefing books, BTD, PIPs, SAPs, and safety periodic reports, providing risk-benefit framing and clinical rationale. • Support qualification of pharmacodynamic and disease markers for early assessment of efficacy. • May provide clinical strategic feedback on in-licensing opportunities. Qualifications and Skills Essential • 8 years’ experience, an MD, or equivalent degree from an accredited university, or an MD (or equivalent) plus a PhD, with specialty or experience in the immunology or neuroimmunology therapeutic area. Cell-therapy experience is ideal. • Postgraduate subspecialty training and board